Genetically engineered Newcastle disease virus for prostate cancer: a magic bullet or a misfit

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

The prostate-specific antigen-retargeted Newcastle disease virus discussed in the manuscript was developed through fundnig from US Department of Defense under a ‘congressionally directed Medical Research Program for prostate cancer’ concept award to S Elankumaran. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.